This open-label, retrospective, observational study will evaluate the compliance to RoActemra/Actemra (tocilizumab) therapy in patients with moderate to severe rheumatoid arthritis. Six months data will be collected from patients records.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01375478?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
